Dec 17th or so of last year this stk dead dropped from $7. They must of missed in a trial.../
ALDX has $7-$11 Potential. They also have an analyst day tomorrow-!
Aldeyra update 'far from mundane,' says Alliance Global Partners 03/18 ALDX Alliance Global Partners analyst Matt Cross called Aldeyra's earnings update for Q4 "far from mundane," noting that company previewed several major 2022 data catalysts but also introduced three new studies of reproxalap in the dry eye disease and allergic conjunctivitis indications. The analyst, who thinks Aldeyra will "contribute another substantive layer to its story" at its R&D day on March 29 and argues that the company's retinal disease programs are slated to make "noteworthy strides" in the back half of the year, keeps a Buy rating and $24 price target on the shares.